Loading clinical trials...

Autophagy in Paediatric Crohn's Disease | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Autophagy in Paediatric Crohn's Disease

Autophagic Activity Characterization in Pediatric Crohn's Disease

NCT05842564•Hospices Civils de Lyon

Summary

Crohn's disease is a multifactorial complex disease resulting in a between microbiota and immune system. Indeed, GWAS (Genome-Wide Association Studies) association study pinpointed polymorphisms as genes susceptibility on more than 200 loci. Among them genes coding for proteins involved in autophagy machinery (i.e: ATG16L1, IRGM et NDP52). Autophagy is a ubiquitous intracellular mechanism mandatory for protein and microorganism recycling. So far, the role of autophagy in gut inflammation and intestinal homeostasis in Crohn's disease patients is partially understand. Then, investigators plan to evaluate, on native cells, the autophagic flux in pediatric patients suffering of a Crohn's disease compare to controls.

Eligibility

Age

6 - 17 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•For Crohn's Disease group :
•Age between 6 and 17 inclusive
•Patients with a weight \> 25 kg at the time of inclusion
•Patients with Crohn's disease requiring ileocolonoscopy (diagnosis or follow-up)
•Mild to severe Crohn's disease consistent with PCDAI disease activity score
•Patients on nutritional therapy (Modulen/Modulife), corticosteroids, salicylic derivatives, immunosuppressants, biotherapies (anti-TNF, vedolizumab and ustekinumab) or without treatment
•Consent form signed by the patient or the holder(s) of parental authority.
•Affiliation to a social security scheme or beneficiaries of a similar scheme.
•For Control group:
•Between 6 and 17 years old included
+5 more criteria

Exclusion Criteria

•Refusal to participate in the protocol
•Intercurrent infection
•Ongoing antibiotic treatment
•Patient involved in another interventional study protocol including an exclusion period still in progress at pre-inclusion
•Pregnant, parturient or breastfeeding women (on questioning)
•Persons deprived of their liberty by a judicial or administrative decision
•Persons subject to psychiatric care
•Persons admitted to a health or social establishment for purposes other than research

Locations (1)

Service Hépatologie, Gastroentérologie et Nutrition pédiatrique, Hôpital Femme Mère Enfant, HCL

Bron, France

Key Dates

Start Date

January 1, 2025

Primary Completion Date

April 1, 2027

Completion Date

April 1, 2027

Last Updated

December 12, 2024

Enrollment

ESTIMATED participants

Conditions

Crohn DiseasePediatric Crohns Disease

Interventions

Blood samples

OTHER

Biopsies

OTHER

Contacts

Rémi DUCLAUX-LORAS, MD, PhD

CONTACT

0472357050 remi.duclaux-loras@chu-lyon.fr

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Autophagy in Paediatric Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study